Evaluation of Antidiabetic Potential and Biochemical Parameters of Aqueous Pod Extract of Moringa oleifera in Alloxan Diabetic Rats
doi.org/10.26538/tjnpr/v4i2.5
Keywords:
Moringa oleifera pod,, diabetes,, oral glucose tolerance,, lipids,, transaminasesAbstract
Moringa oleifera leaves and seeds are sold in Nigeria as nutraceutical for the treatment of various diseases including diabetes mellitus. It may also be possible that the pod of M. oleifera could have antidiabetic effect and lower plasma lipid in which diabetic patients are predisposed to. Hence there is the need to evaluate the potential of the aqueous pod extract of M. oleifera as an antidiabetic and lipid lowering agent. Acute blood glucose lowering effect of varying doses (100, 200 and 400 mg/kg) of the aqueous pod extract of M. oleifera and glibenclamide (10 mg/kg) on normal and alloxan-induced diabetic rats was investigated. The rats were treated daily for 21 days with the most effective dose (200 mg/kg, orally) and its effects on blood glucose, oral glucose tolerance, body weight, biochemical parameters and lipid indices were evaluated. Results of the study showed significant (p<0.05) reduction in blood glucose level. Daily administration of the extract significantly (p<0.05) improved glucose tolerance, attenuated plasma lipids levels, alanine transaminase and aspartate transaminase in the diabetic group. There was positive improvement in the body weight of the diabetic rats after treatment. The aqueous pod extract of M. oleifera exhibited significant antidiabetic and lipid lowering effects, which may be due to the presence of flavonoids, which are known antioxidants or possible regeneration of the pancreatic β-cells.
References
Baynest HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabet Metab. 2015; 6(5):1-9.
Teixeira CC, Rava CA, Da Silva PM, Melchior R, Argenta R, Anselmi F, Almeida CRC, Fuchs FD. Absence of antihyperglycemic effect of jambolan in experimental and clinical models. J Ethnopharmacol. 2000; 71:343-347.
World Health Organization Technical Report Series. WHO; 1980. The WHO Expert Committee on diabetes mellitus. 1980.
World Health Organization Study group on diabetes mellitus. Technical Report Series No. 844, World Health Organization, Geneva. 1994; 78–79.
Elujoba AA, Odeleye OM, Ogunyemi CM. Traditional medicine development for medical and dental primary health care delivery system in Africa. J Trad Compl Alt Med. 2005; 2:46-61.
Duckworth WC, Hamel FG, Peavy DE. Hepatic metabolism of insulin. Am J Med. 1988; 85: 71–76.
Mooradian AD and Thurman JE. Drug Therapy of Postprandial Hyperglycaemia. Drug. 1999; 57(1):19–29.
Harris EH. Elevated Liver Function Tests in Type 2 Diabetes. Clin Diabet. 2005; 23(3): 115-119.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844–1850.
Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City Diabetes Study. Diabetes Care 2005; 28: 1757–1762.
Cho NH, Jang HC, Choi SH, Kim HR, Lee HK, Chan JCN et al. Abnormal Liver Function Test Predicts Type 2 Diabetes. Diabetes Care 2007; 30(10): 2566-2568.
Anwar F, Latif S, Ashraf M, Gilani AH. Moringa Oleifera: A food plant with multiple medicinal uses. Phytother Res. 2007; 21:17-25.
Gupta R, Mathur M, Bajaj KV, Katariya P, Yadav S, Kamal R et al. Evaluation of antidiabetic and antioxidant activity of Moringa oleifera in experimental diabetes. J Diabetes 2012; 4(2):164-171.
Kar A, Choudhary BK, Bandyopadhyay NG. Comparative evaluation of hypoglycemic activity of some Indian medicinal plants in alloxan diabetic rats. J Ethnopharmacol. 2003; 84:105–108.
Jaiswal D, Rai PK, Kumar A, Mehta S, Watal G. Effect of Moringa oleifera Lam. leaves aqueous extract therapy on hyperglycemic rats. J Ethnopharmacol. 2009; 123:392–396.
Ghasi S, Nwobodo E, Ofili JO. Hypocholesterolemic effects of crude extract of leaf of Moringa oleifera Lam. in high-fat diet fed Wistar rats. J Ethnopharmacol. 2000; 69:21–25.
Mehta K, Balaraman R, Amin AH, Bafna PA, Gulati OD. Effect of fruits of Moringa oleifera on the lipid profile of normal and hypercholesterolemic rabbits. J Ethnopharmacol. 2003; 86: 191–195.
Cáceres A, Cabrere O, Morales O, Mollinedo P, Mendia P. Pharmacological properties of Moringa oleifera. 1: Preliminary screening for antimicrobial activity. J Ethnopharmacol. 1991; 33:213-6.
Cáceres A, Saravia A, Rizzo S, Zabala L, De Leon E, Nave F Pharmacologic properties of Moringa oleifera. 2: Screening for antispasmodic, anti-inflammatory and diuretic activity. J Ethnopharmacol. 1992; 36:233-237.
Rathi BS, Bodhankar SL, Baheti AM. Evaluation of aqueous leaves extract of Moringa oleifera Linn. for wound healing in albino rats. Ind J Exp Biol. 2006; 44:898-901.
Sulaiman MR, Zakaria ZA, Bujarimin AS, Somcent MN, Israf DA, Moin S. Evaluation of Moringa oleifera aqueous extract for antinociceptive and anti-inflammatory activities in animal models. Pharm Biol. 2008; 46:838-845.
Adejumo OE, Kolapo AL, Folarin AO. Moringa oleifera Lam. (Moringaceae) grown in Nigeria: In vitro antisickling activity on deoxygenated erythrocyte cells. J Pharm Bioall Sci. 2012; 4(2):118-122.
Guide for the Care and Use of Laboratory Animals 1996. Institute of Laboratory Animal Research (ILAR) Commission on life Science, National Research Council. Available from: http://www.nap.edu/openbook.php?record_id = 5140&page= 21[Last accessed on 2018 Mar 22].
Talukdar AD, Choudhary MD, Chakraborty M, Dutta BK. Phytochemical screening and TLC profiling of plant extracts Cyathea gigantea (Wall. Ex. Hook.) Haltt. and Cyathea brunoniana. Wall.ex.Hook. (Cl.& Bak.). Assam University Journal of Science & Technology: Biol Environ Sci 2010; 5(1):70-74.
Harborne JB. Phytochemical Methods - A Guide to Modern Techniques of Plant Analysis. Chapman and Hall, London 1998; 182-190.
Guidance document on acute oral toxicity testing Series on testing and assessment No. 24. Organization for Economic Cooperation and Development OECD environment. Paris: Health and Safety publications; 1996. Available from: http://www.oecd.org/ehs[Last accessed on 2018 Mar 22].
Litchfield JT Jr. and Wilcoxon F. A simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics 1949; 97:399-408.
Waynforth BH. Injection techniques. In: Experimental and Surgical Techniques in the Rat. Academic Press, London, NY, USA. 1980. 30-61 p.
Rhiouani H, El-Hilaly J, Israili ZH, Lyoussi B. Acute and subchronic toxicity of an aqueous extract of the leaves of Herniaria glabra in rodents. J Ethnopharmacol. 2008; 118:378-386.
Barham D and Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 1972; 97: 142-145.
Menezes FG, Neves ACO, De Lima DF, Lourenço SD, Da Silva LC, De Lima KMG. Bioorganic Concepts involved in the Determination of Glucose, Cholesterol and Triglycerides in Plasma Using the Enzymatic Colorimetric Method. Quím. Nova 2015; 38(4):588-594.
Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20(4):470-475.
Grove TH. Effect of reagent pH on determination of high density lipoprotein cholesterol by precipitation with sodium phosphotungstate-magnesium. Clin Chem. 1979; 25:560-564.
Friedewald WT, Levy RI, Fredrickson DS Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499-502.
Bergmeyer HU, Horder M, Rej R. Approved Recommendation on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes. Part 2. IFCC Method for Aspartate Aminotransferase. J Clin Chem. ClinBiochem. 1986; 24: 497-510.
Bergmeyer HU, Horder M, Rej R Approved Recommendation on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes. Part 3. IFCC Method for Alanine Aminotransferase. J Clin Chem Clin Biochem. 1986; 24:481-495.
Kingsley GR. The direct Biuret method for the determination of serum protein is as applied to photoelectric and visual colorimetry. J Lab Clin Med. 1942; 27:840-845.
Alberti KGMM, Zimmet PZ (Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Disguises and classification of diabetes mel. litus. Provisional Report of WHO consultations. Diabet Med. 1998; 15:539-553.
Owolabi, MA, Jaja, SI, Olatunji, OJ, Oyekanmi, OO, Adepoju, S. Attenuation of Oxidative Damage in Alloxan Induced Diabetic Rabbits Following Administration of the Extract of the Leaves of Vernonia amygdalina. Free Rad Antiox. 2011; (1)3:94-101.
Takasu N, Komiya I, Asawa T, Nagasawa Y, Yamada T. Streptozocin- and Alloxan-Induced H2O2 Generation and DNA Fragmentation in Pancreatic Islets: H2O2 as Mediator for DNA Fragmentation. Diabetes 1991; 40(9):1141-1145.
Gwarzo MY, Nwachuku VA, Lateef AO. Prevention of Alloxan Induced Diabetes Mellitus in Rats by Vitamin A Dietary Supplement. Asian J Anim Sci 2010; 4(4): 190-196.
Ali SN and Khan MR. Antidiabetic Effect of Sida cordata in Alloxan Induced Diabetic Rats. BioMed Res Int. 2014; 2014:1-15.
Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med. 2007; 7(1):24-29.
Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011; 28:213–226.
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8:728–742.
Derosa G and Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012; 8:899–906.
Suryawanshi NP, Bhutey AK, Nagdeote AN, Jadhav AA, Manoorkar GS. Study of Lipid Peroxide and Lipid Profile In Diabetes Mellitus. Indian J Clin Biochem 2006; 21(1):126-130.
Assmann G, Gotto AM. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004; 109: III8-III14.
Ogbera AO, Fasanmade OA, Chinenye S, Akinlade A. Characterization of lipid parameters in diabetes mellitus-a Nigerian report. Int Arch Med. 2009; 2:19-23.
Sattar N, Scherbakova O, Ford I, O’Reilly DS, Stanley A, Forrest E et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabet. 2004; 53: 2855–2860.
Owolabi MA, Ukpo GE, Ogah CO, Oloruntoba OO, Kehinde O. Evaluation of the Antihyperlipidemic and Antioxidant Properties of the Aqueous Leaf Extract of Camellia sinensis in Oil-induced Hyperlipidemic Rats. Trop J Nat Prod Res. 2017; 1(4):176-181.
Saligram S, Williams EJ, Masding MG. Raised liver enzymes in newly diagnosed Type 2 diabetes are associated with weight and lipids, but not glycaemic control. Indian J Endocrinol Metab. 2012; 16(6):1012–1014.
Messeri S, Messerini L, Vizzutti F, Laffi G, Marra F. Glycogenic hepatopathy associated with type 1 diabetes mellitus as a cause of recurrent liver damage. Annals of Hepatol. 2012;11(4):554–558.
Hudacko RM, Manoukian AV, Schneider SH, Fyfe B. Clinical resolution of glycogenic hepatopathy following improved glycemic control. J Diabet Complic 2008; 22(5):329–330.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
